scholarly article | Q13442814 |
P356 | DOI | 10.1002/MDS.26892 |
P698 | PubMed publication ID | 27911006 |
P50 | author | Janice Holton | Q30089851 |
Glenda Halliday | Q45304807 | ||
Nicolas Dzamko | Q57321778 | ||
Wilma van de Berg | Q57421896 | ||
Rina Bandopadhyay | Q106926125 | ||
P2093 | author name string | Shigeo Murayama | |
Marc F Bolliger | |||
Ye Zhao | |||
Junko Takahashi-Fujigasaki | |||
Masaki Takao | |||
Akiko Uchino | |||
R Jeremy Nichols | |||
Amanda M Gysbers | |||
Sandrine Wauters | |||
P2860 | cites work | Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity | Q22254785 |
LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models | Q24304959 | ||
LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study | Q24307455 | ||
Localization of LRRK2 to membranous and vesicular structures in mammalian brain | Q24318643 | ||
Interplay of LRRK2 with chaperone-mediated autophagy | Q24322747 | ||
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization | Q24339094 | ||
Genome-wide association study reveals genetic risk underlying Parkinson's disease | Q24646654 | ||
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease | Q28292932 | ||
The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling | Q28480459 | ||
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease | Q29614900 | ||
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study | Q29614953 | ||
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity | Q29615144 | ||
Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy | Q33920691 | ||
Arsenite stress down-regulates phosphorylation and 14-3-3 binding of leucine-rich repeat kinase 2 (LRRK2), promoting self-association and cellular redistribution | Q33985278 | ||
An emerging role for LRRK2 in the immune system | Q34300438 | ||
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. | Q35780973 | ||
Large-scale replication and heterogeneity in Parkinson disease genetic loci | Q36149955 | ||
LRRK2 inhibition attenuates microglial inflammatory responses | Q36493605 | ||
MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein. | Q36525872 | ||
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization | Q36780383 | ||
Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies | Q36929535 | ||
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria | Q37631959 | ||
LRRK2 and neuroinflammation: partners in crime in Parkinson's disease? | Q38198207 | ||
Neuropathology of α-synuclein propagation and braak hypothesis | Q38580816 | ||
LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease | Q39432630 | ||
Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition | Q39457004 | ||
LRRK2 dephosphorylation increases its ubiquitination | Q41785779 | ||
Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain | Q48162781 | ||
Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain | Q48372083 | ||
Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. | Q54529101 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Parkinson's disease | Q11085 |
phosphorylation | Q242736 | ||
P304 | page(s) | 423-432 | |
P577 | publication date | 2016-12-02 | |
P1433 | published in | Movement Disorders | Q1486418 |
P1476 | title | LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies | |
P478 | volume | 32 |
Q89484985 | An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts |
Q61849485 | Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology |
Q47139369 | Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers |
Q90375075 | GTP-binding inhibitors increase LRRK2-linked ubiquitination and Lewy body-like inclusions |
Q96953324 | LRRK2 Phosphorylation, More Than an Epiphenomenon |
Q90638116 | Leucine Rich Repeat Kinase 2 and Innate Immunity |
Q54978235 | Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo. |
Q64759312 | Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders |
Q59797902 | Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice |
Q47281413 | Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers |
Q39263032 | Targeting LRRK2 in Parkinson's disease: an update on recent developments |
Q55442883 | The Enzymatic Core of the Parkinson’s Disease-Associated Protein LRRK2 Impairs Mitochondrial Biogenesis in Aging Yeast. |
Q64811522 | The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors |
Search more.